The Evaluation of Fasting Glucose Plasma (FGP) in Hypertensive Patients using Calcium Channel Blocker (CCB) Drug Class in Undata Regional Hospital

Background: Hypertension plays a major role in the development of heart disease which is one of the most leading causes of death worldwide. Antihypertensives must be selected carefully to avoid affecting metabolic parameters. A risky case involving the increase of glucose plasma levels using Calcium Channel Blocker (CCB) antihypertensive, amlodipine, has been reported. Objectives: This study aims to examine the effects of CCB treatments on blood glucose levels in hypertensive patients at the Undata District General Hospital of Central Sulawesi Province. Material and Methods: This study used a cross-sectional design with a prospective approach. The instruments & materials used in this study are Accu-Chek Performa glucometer along with the patient's blood sample material. The research subjects were 31 patients who met the inclusion criteria of 1) patients who had been treated with CCB therapy for 3 months, 2) were not diagnosed with diabetes mellitus, and 3) did not use drugs that might affect blood glucose levels. Results: The results showed an average value of fasting glucose plasma (FGP) levels of hypertension patients using CCB class showed an increase from baseline 124,619 mg/dL to 141,612 mg/dL with a difference of 16,993 mg/dL. Conclusions: Statistical analysis conducted also obtained a significance value of p 0,000 which indicates that the use of amlodipine can significantly increase fasting patients' glucose plasma levels. If observed clinically, this increase in fasting glucose plasma values ​​falls into the category of mild to moderate hyperglycemic.